Are Juxtapleural Nodules Cancerous?

Most juxtapleural nodules found on CT scans are not cancerous. These small growths sitting against the lung’s pleural surface are overwhelmingly benign, with intrapulmonary lymph nodes accounting for a large share of them. Updated screening guidelines from both the International Early Lung Cancer Action Program and Lung-RADS 2022 now classify small juxtapleural nodules with classic benign features as likely harmless, recommending routine annual follow-up rather than urgent workup.¹ That said, a minority of pleural-attached nodules do turn out to be malignant, and the features that separate the worrisome ones from the harmless ones are worth understanding.

Why Most Juxtapleural Nodules Are Benign

The most common explanation for a small nodule hugging the pleura is that it is an intrapulmonary lymph node. These are normal bits of immune tissue scattered throughout the lungs, and several studies with pathological confirmation have shown they make up a considerable portion of incidentally detected pulmonary nodules on high-resolution CT.² They do not require follow-up once correctly identified. In a pediatric study that examined 36 pathologically confirmed benign intrapulmonary lymph nodes, about 42% were pleura-based, with a mean size of only 3.6 mm. Nearly 70% had a triangular shape, and all were smooth-edged and solid without calcification or fat.³ That triangular or lentiform shape, sitting flat against the pleural surface with smooth margins, is essentially the calling card of a harmless lymph node.

Beyond lymph nodes, other benign causes of juxtapleural nodules include granulomas from old infections (tuberculosis, fungal exposures), areas of rounded atelectasis where the lung partially collapses and folds against the pleura, and inflammatory conditions. Occupational dust exposure can also produce subpleural nodules. In talcosis, for instance, CT scans show small centrilobular and subpleural nodules, sometimes with high-attenuation foci indicating talc deposits.⁴ Silicosis and coal workers’ pneumoconiosis can produce similar patterns. If you have a history of mining, construction work, or other dust-heavy occupations, your doctor may recognize these nodules as occupational rather than neoplastic.

The Features That Raise Suspicion

When radiologists evaluate a pleural-attached nodule, they are not just asking whether it exists. They are looking at a checklist of shape, size, margin, and location features that collectively push the probability toward benign or malignant. According to Lung-RADS version 2022, most small solid juxtapleural nodules under 10 mm with smooth margins and an oval, lentiform, or triangular shape can be managed with routine annual follow-up. But when a nodule shows lobulation, spiculation, or interval growth, it should not be dismissed.⁵

A large study examining solid pleural-attached nodules on thin-section CT identified several independent predictors of malignancy through multivariate analysis. Smoking history roughly doubled the odds of a malignant nodule. Location mattered too: nodules touching the mediastinal pleura had about three times the odds of being malignant compared to those along the costal (outer) pleural surface. Nodules larger than about 15.6 mm in diameter carried higher risk, and lobulated margins were one of the strongest predictors, with nearly nine times the odds of malignancy. A narrow “basement,” meaning the nodule had a small contact footprint with the pleura rather than sitting flat, also strongly predicted cancer. The combined model using all these features had a sensitivity of 82% and specificity of 77%.⁶

In practical terms, a small, smooth, flat-based triangular nodule in the lower lobes of a nonsmoker is almost certainly a lymph node. A larger, lobulated, narrow-based nodule abutting the mediastinal pleura in a longtime smoker deserves closer attention and likely further workup.

When a Juxtapleural Nodule Is Cancer

While the odds favor benign diagnoses, cancerous nodules certainly do appear in the juxtapleural zone. In a biopsy series of 196 subpleural lesions, roughly 65% turned out to be non-small cell carcinomas, and another 13% were other lung malignancies or metastatic tumors. About 15% were due to inflammation or infection, with the remainder being other benign diagnoses.⁷ It is worth noting that this series specifically involved lesions suspicious enough to warrant biopsy, so the malignancy rate is far higher than what you would see in an unselected screening population. Most juxtapleural nodules found on screening CT never reach the biopsy stage because they look benign on imaging.

Lung adenocarcinoma is the most common primary cancer in the subpleural zone. A study of 447 early-stage non-small cell lung cancers three centimeters or smaller found that adenocarcinoma accounted for the vast majority, with squamous cell carcinoma and rarer subtypes making up a small fraction.⁸ Metastatic disease from cancers elsewhere in the body can also seed the lung’s periphery and show up as subpleural nodules. These metastatic deposits need to be considered in any patient with a known cancer history and new lung nodules.

Visceral Pleural Invasion and Why It Matters for Staging

For subpleural nodules that do turn out to be cancerous, one of the key questions is whether the tumor has invaded the visceral pleura, the thin membrane lining the lung’s surface. This distinction changes how the cancer is staged. A small tumor that has pushed into the pleura gets bumped up from a T1 to a T2 classification, which can affect treatment decisions and prognosis.

Certain CT features help predict whether visceral pleural invasion has occurred. In a study of 188 peripheral adenocarcinomas presenting as subsolid nodules, about 19% had visceral pleural invasion at pathology. Pleural contact, pleural thickening visible on CT, a solid component making up more than half the nodule, and overall nodule size greater than 20 mm were all significant independent predictors. Pleural contact alone carried an adjusted odds ratio above 8, meaning nodules touching the pleura were far more likely to have invasion than those that did not.⁹ Pure ground-glass nodules, however, had zero cases of visceral pleural invasion in that study, which is reassuring for patients whose nodules lack any solid component.

PET/CT scans can add information here. A study evaluating FDG PET/CT for predicting visceral pleural invasion found that the distance between the nodule and the pleura and the nodule’s metabolic activity (measured as SUVmax) were both significant independent predictors. A nodule less than about 4.5 mm from the pleura had a sensitivity of nearly 97% for predicting invasion, and combining that distance with metabolic activity pushed the model’s overall performance higher, reaching a sensitivity above 96% and specificity above 71%.¹⁰

How Doctors Decide Whether to Watch or Act

The approach to a juxtapleural nodule follows a spectrum from “ignore it” to “biopsy it now,” and the revised Fleischner Society guidelines give radiologists and clinicians a framework for navigating that range. The 2017 update raised the minimum size threshold for routine follow-up and gave recommended intervals as ranges rather than rigid time points, allowing doctors and patients to factor in individual risk.¹ For most small solid nodules in low-risk patients, this means no follow-up at all below a certain size, and a single follow-up scan at 6 to 12 months for slightly larger ones.

Volumetric analysis, which tracks the three-dimensional size of a nodule over time, is increasingly used to distinguish growing nodules from stable ones. In a screening study of 153 nodules, about 68% of malignant nodules grew compared to 33% of benign ones. Among growing solid nodules, malignant ones had a volume doubling time of roughly 204 days versus 386 days for benign nodules. When the doubling time was under 400 days, 92% of growing malignant solid nodules fell in that range compared to 58% of benign ones. So a nodule that doubles in volume in well under a year is more worrisome, though some benign nodules grow at a similar pace, which is why no single metric is definitive.¹¹

For nodules that do need tissue sampling, CT-guided needle biopsy is the standard approach for subpleural lesions. One complication worth knowing about: subpleural nodules within about 2 cm of the pleural surface actually carry a higher risk of pneumothorax (air leaking into the chest cavity) after biopsy. One study found that lesions at this shallow depth represented about a third of lung lesions but accounted for 71% of all post-biopsy pneumothoraces.¹² This may seem counterintuitive since the needle does not have far to travel, but the mechanics of puncturing the pleura at a shallow angle explain the higher leak rate. Most of these pneumothoraces are small and resolve on their own, but it is something your interventional radiologist will discuss with you.

Surgical Approaches for Suspicious Subpleural Nodules

When a subpleural nodule needs to come out, whether for diagnosis or treatment, video-assisted thoracoscopic surgery (VATS) is the typical approach. The challenge with small peripheral nodules is that the surgeon cannot always feel them during the procedure. CT-guided marking before surgery, often using tiny metal coils placed near the nodule, helps the surgeon find and remove the right spot. In one series of 63 patients, the success rate for coil-guided wedge resection was high, with the average operation taking about 84 minutes and the average hospital stay coming in at just over 2 days. Complications were uncommon: about 5% had intraoperative issues, and 8% had postoperative problems like air leaks or bleeding.¹³ About 17% of patients ultimately needed a completion lobectomy, typically because the nodule turned out to be a cancer that required a wider margin.

This staged approach, starting with a small wedge resection and escalating to a lobectomy only if needed, is particularly well suited to subpleural nodules where the diagnosis is uncertain. It avoids removing an entire lobe for what might be a benign lymph node while still allowing definitive cancer treatment if the frozen section comes back positive.

The Anxiety Factor

Getting a CT report that mentions a lung nodule, juxtapleural or otherwise, can be deeply unsettling. A quality improvement study surveying patients with pulmonary nodules found that about 60% worried about their nodule at least once a month, and roughly 21% worried about it daily. Only about a quarter never worried at all. The average anxiety score was nearly 5 out of 10.¹⁴ This is a real and underappreciated cost of incidental findings on CT scans. If you have been told you have a juxtapleural nodule and your doctor recommends annual follow-up rather than immediate action, that recommendation is based on decades of data showing that small, morphologically benign nodules almost never turn out to be cancer. The waiting is not negligence; it is evidence-based restraint.

The psychological toll can be compounded by vague radiology reports. Understanding that “juxtapleural” simply means “next to the pleura” and that a smooth, small, triangular nodule in that location is almost certainly a normal lymph node can go a long way toward easing the worry. If your report uses phrases like “likely benign intrapulmonary lymph node,” that is radiologist shorthand for “we are confident this is nothing.”

How AI Is Changing Nodule Detection

Artificial intelligence is increasingly involved in the detection and monitoring of lung nodules, including those near the pleura. Computer-aided detection systems perform better at finding subsolid nodules when they work with thin CT slices (1 mm) compared to thicker slices (3 or 5 mm). A deep learning-based algorithm that artificially reduces slice thickness can improve detection sensitivity even when the original scan used thicker slices.¹⁵ This matters because many screening and incidental CT scans are not performed with the thinnest possible slices, and AI post-processing can partially compensate.

The frontier for AI in this space is growth prediction. Rather than just finding nodules, researchers are developing models that analyze a nodule’s shape, density, and change over time to predict whether it will grow and how fast. The volume doubling time of a nodule is a key metric in determining malignancy risk, and AI could theoretically automate that calculation more precisely than manual measurements. Current models still struggle with complex nodule shapes and data from different scanners and institutions, so the technology is not yet ready to replace clinical judgment.¹⁶ But for patients undergoing serial scans for a juxtapleural nodule, AI-assisted volumetry may soon offer earlier and more reliable detection of subtle growth.

False Negatives in Screening

One of the trickier aspects of juxtapleural nodules is that their very location can sometimes cause radiologists to give them a free pass they do not deserve. Because the majority of small pleura-based nodules are benign lymph nodes, there is a cognitive bias toward dismissing them. Perifissural and pleura-based nodules are frequently interpreted as intrapulmonary lymph nodes, and the guidelines support conservative management of classic-appearing ones. But when a nodule has nonclassic features, particularly new lobulation, spiculation, or interval growth, that default assumption can lead to a missed cancer.⁵

Pleural tags, extensive pleural contact, localized pleural thickening, and pleural indentation are all signs that a nodule may be interacting with the pleura in ways that suggest invasion rather than simple proximity. These features are sometimes subtle, and PET/CT does not reliably detect very small nodules in this region. Standard whole-body PET/CT found fewer nodules per patient than high-resolution reformats or dedicated breath-hold chest CT, with the gap especially pronounced for nodules 8 mm or smaller.¹⁷ So if you are being followed for a juxtapleural nodule that has changed over time, a thin-section dedicated chest CT is generally more informative than a standard PET scan for characterizing the nodule itself.

The reassuring takeaway for most people is that the system works. Guidelines are designed to catch the rare cancers that masquerade as benign juxtapleural nodules through serial imaging, and the vast majority of people with these findings will never need anything beyond a follow-up scan or two before the nodule is confidently dismissed.